Causes of mortality among tuberculosis and HIV co-infected patients in chiang rai, northern Thailand

HIV/AIDS - Research and Palliative Care

Volumn 4, Issue , 2012, Pages 159-168

  Kantipong, Pacharee ^a   Murakami, Kuniko ^b   Moolphate, Saiyud ^c   Aung, Myo Nyein ^d,e   Yamada, Norio ^b  

^a Chiangrai Prachanukroh Hospital   (Thailand)

^b RESEARCH INSTITUTE OF TUBERCULOSIS   (Japan)

^c TB/HIV Research Project   (Thailand)

^d JUNTENDO UNIVERSITY   (Japan)

^e University of Public Health   (Myanmar)

Author keywords

Antiretroviral therapy; Cause of death; CD4; Coinfection; Human immunodeficiency virus; Tuberculosis

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; FLUCONAZOLE; TUBERCULOSTATIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AIDS RELATED COMPLEX; ARTICLE; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; DISEASE ASSOCIATION; DISEASE REGISTRY; FEMALE; HEALTH CARE ACCESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIXED INFECTION; PREDICTION; RETROSPECTIVE STUDY; THAILAND; TUBERCULOSIS; TUBERCULOUS MENINGITIS;

EID: 84872969257     PISSN: None     EISSN: 11791373     Source Type: Journal    
DOI: 10.2147/HIV.S33535     Document Type: Article

References (41)

1. World Health Organiztion TB/HIV fact sheets. 2011. Available from: http://www.who.int/tb/publications/TBHIV_Facts_for_2011.pdf. Accessed June 4, 2012.
2. Cain K P, Anekthananon T, Burapat C, et al. Causes of death in HIV- infected persons who have tuberculosis, Thailand. Emerg Infect Dis. 2009;15(2):258-264.
3. Krentz H, Kliewer G, Gill M. Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003. HIV Med. 2005;6(2):99-106.
4. Palella FJJ, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV Outpatient Study. J Acquir Immune Defc Syndr. 2006;43(1):27-34.
5. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338(13):853-860.
6. Saraceni V, King BS, Cavalcante SC, et al. Tuberculosis as primary cause of death among AIDS cases in Rio de Janeiro, Brazil. Int J Tuberc Lung Dis. 2008;12(7):769-772.
7. Straetemans M, Bierrenbach AL, Nagelkerke N, Glaziou P, van der Werf MJ. The effect of tuberculosis on mortality in HIV positive people: a meta-analysis. PLoS One. 2010;5(12):e15241.
8. Kyeyune R, den Boon S, Cattamanchi A, et al. Causes of early mortality in HIV-infected TB suspects in an East African referral hospital. J Acquir Immune Defc Syndr. 2010;55(4):446-450.
9. Au-Yeung C, Kanters S, Ding E, et al. Tuberculosis mortality in HIV- infected individuals: a cross-national systematic assessment. Clin Epidemiol. 2011;3:21-29.
10. World Health Organization. TB/HIV Facts 2010. Available from: http://www.who.int/tb/challenges/hiv/factsheet_hivtb_2010.pdf. Accessed November 4, 2011.
11. World Health Organization. Global Tuberculosis Control 2010. Available from: http://www.who.int/tb/features_archive/global_report2010_launch_11nov10/en/index.html. Accessed August 12, 2012.
12. World Health Organization. South-East Asia Regional Office. Tuberculosis Control in South-East Asia Region 2012. Available from: http://www.searo.who.int/LinkFiles/Tuberculosis_WHO-TB-Report-2012.pdf. Accessed April 24, 2012.
13. US Global Health Policy. TB: HIV prevalence incident TB cases 2009. Available from: http://www.globalhealthfacts.org/topic.jsp?i=26. Accessed August 12, 2012.
14. World Health Organization. Tuberculosis country profiles 2012. Available from: http://www.who.int/tb/country/data/profles/en/index.html. Accessed April 24, 2012.
15. Moolphate S. TB HIV situation in Chiang Rai province. Report presented at the 14th TB HIV Annual Meeting, January 13, 2011, Chiang Rai, Thailand.
16. Ansari NA, Kombe AH, Kenyon TA, et al. Pathology and causes of death in a group of 128 predominantly HIV-positive patients in Botswana, 1997-1998. Int J Tuberc Lung Dis. 2002;6(1):55-63.
17. Mankhatitham W, Lueangniyomkul A, Manosuthi W. Hepatotoxicity in patients co-infected with tuberculosis and HIV-1 while receiving non- nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and rifampicin-containing anti-tuberculosis regimen. Southeast Asian J Trop Med Public Health. 2011;42(3):651-658.
18. World Health Organization. Treatment of Tuberculosis: Guidelines for National Programmes. 4th ed. Geneva, Switzerland: World Health Organization; 2009.
19. Department of Disease Control Ministry of Public Health. Thailand National Antiretroviral Treatment Guideline (2006/2007) 2007. Available from: http://www.gfaidscare.com/doc/Guideline%20English%20Part_one[1].pdf. Accessed August 12, 2012.
20. World Health Organization Stop TB Department. Treatment of tuberculosis: guidelines for national programmes. 4th ed. Available from: http://www.who.int/tb/publications/tb_treatmentguidelines/en/index.html. Accessed June 27, 2012.
21. Akksilp S, Karnkawinpong O, Wattanaamornkiat W, et al. Antiretroviral therapy during tuberculosis treatment and marked reduction in death rate of HIV-infected patients, Thailand. Emerg Infect Dis. 2007;13(7):1001-1007.
22. Sanguanwongse NMD, Cain KPMD, Suriya PMS, et al. Antiretroviral therapy for HIV-infected tuberculosis patients saves lives but needs to be used more frequently in Thailand. J Acquir Immune Defc Syndr. 2008;48(2):181-189.
23. Varma J, Nateniyom S, Akksilp S, et al. HIV care and treatment factors associated with improved survival during TB treatment in Thailand: an observational study. BMC Infect Dis. 2009;9(1):42.
24. Kingkaew N, Sangtong B, Amnuaiphon W, et al. HIV-associated extrapulmonary tuberculosis in Thailand: epidemiology and risk factors for death. Int J Infect Dis. 2009;13(6):722-729.
25. Nissapatorn V. Lessons learned about opportunistic infections in southeast Asia. Southeast Asian J Trop Med Public Health. 2008;39(4): 625-641.
26. Torok ME, Yen NT, Chau TT, et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-associated tuberculous meningitis. Clin Infect Dis. 2011;52(11):1374-1383.
27. Tansuphasawadikul S, Saito W, Kim J, et al. Outcomes in HIV-infected patients on antiretroviral therapy with tuberculosis. Southeast Asian J Trop Med Public Health. 2007;38(6):1053-1060.
28. Moolphate S, Aung MN, Nampaisan O, et al. Time of highest tuberculosis death risk and associated factors: an observation of 12 years in northern Thailand. Int J Gen Med. 2011;4:181-190.
29. Gutierrez EB, Zanetta DM, Saldiva PH, Capelozzi VL. Autopsy-proven determinants of death in HIV-infected patients treated for pulmonary tuberculosis in Sao Paulo, Brazil. Pathol Res Pract. 2002;198(5): 339-346.
30. Harris JR, Lindsley MD, Henchaichon S, et al. High prevalence of cryptococcal infection among HIV-infected patients hospitalized with pneumonia in Thailand. Clin Infect Dis. 2012;54(5):e43-e50.
31. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents; recommendations for a public health approach, 2010 revision. Available from: http://www.who.int/hiv/pub/arv/adult2010/en/index.html. Accessed August 12, 2012.
32. Sungkanuparph S, Anekthananon T, Hiransuthikul N, et al. Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents: the recommendations of the Thai AIDS Society (TAS) 2008. J Med Assoc Thai. 2008;91(12):1925-1935.
33. Sungkanuparph S, Techasathit W, Utaipiboon C, et al. Thai national guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2010. Asian Biomed (Res Rev News). 2010;4(4):515-528.
34. Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med. 2011;365(16):1492-1501.
35. Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011;365(16): 1482-1491.
36. Blanc F-X, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011;365(16):1471-1481.
37. Lawn SD, Wood R. Timing of antiretroviral therapy for HIV-1- associated tuberculosis. N Engl J Med. 2012;366(5):474-476.
38. Larson BA, Brennan A, McNamara L, et al. Early loss to follow up after enrolment in pre-ART care at a large public clinic in Johannesburg, South Africa. Trop Med Int Health. 2010;15 Suppl 1: 43-47.
39. Chaiyasirinroje B, Aung MN, Moolphate S, et al. Prospective evaluation of simply modified MODS assay: an effective tool for TB diagnosis and detection of MDR-TB. Infect Drug Resist. 2012;5: 79-86.
40. Cain K P, McCarthy KD, Heilig CM, et al. An algorithm for tuberculosis screening and diagnosis in people with HIV. N Engl J Med. 2010;362(8):707-716.
41. Van Rie A, Page-Shipp L, Scott L, Sanne I, Stevens W. Xpert(R) MTB/RIF for point-of-care diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope? Expert Rev Mol Diagn. 2010;10(7):937-946.